Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial

2026/07/27 by Mark D Tyson, Jong-Kil Nam, Shreyas S Joshi +13 · 1 voice
Immunology and Microbiology · Medicine · #Bladder and Urothelial Cancer Treatments #Immune responses and vaccinations #Urinary and Genital Oncology Studies

paper · doi:10.1016/s1470-2045(26)00194-4

openalex publication_date 2026/07/27 · crossref created 2026/07/27 · crossref deposited 2026/07/27 · openalex created_date 2026/07/28 · crossref indexed 2026/07/28 · crossref issued 2026/08/01 · crossref published 2026/08/01 · crossref published-print 2026/08/01 · openalex updated_date 2026/08/02

Citations

• Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment
• Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial

Discussions

• 🚨 BOND-003 Cohort C ➡️ BCG-unresponsive NMIBC + CIS Intravesical cretostimogene, single-arm ph3 👉 CR at any time 75% 🛡️ Grade 3–4 treatment-related AEs 0% ⏱️ Median f/u 25.8 mo 📄 doi.org/10.1016/S [bsky, 0 points, 0 comments]